الفهرس 
Chapter-I : IntroductionOnly 14 pages are availabe for public view
 |  | from | 254 |  |  |
| | | from | 254 | | |
Abstract
Resveratrol with its robust antioxidant activity has been suggested frequently for cancer prevention. Recent reports indicated the cancer treatment potential of resveratrol against several types of neoplasia. Resveratrol was found to block p-glycoprotein and protect from several chemotherapeutic agents’ side effects. Herein, we have assessed the interactive characteristics of resveratrol with docetaxel and doxorubicin and further investigated the molecular bases of this interaction in three different solid tumor cell lines (MCF-7, HeLa and HepG2). Resveratrol per se was found to possess anti-cancer properties; however with relatively low potency in all tested cell lines (ICso ranges from 8.0 to 19. Ij^g/ml). Doxorubicin and docetaxel showed ICso’s ranged from 0.28 to 0.42 jig/ml and from 22.3 to 67.1 ng/ml, respectively. Resveratrol combination with doxorubicin and docetaxel significantly increased the potencies of both chemotherapeutic agents showing IC50’s ranging from 0.07 to 0.2 ug/ml and from 6.2 to 45.7 ng/ml, respectively. The combination index showed synergistic interaction between resveratrol and doxorubicin or docetaxel in MCF-7 cell line, while additive interaction in HeLa and Hep-G2 cell lines. Real time PCR revealed that the expression of BAX and BcL2 were simultaneously elevated due to combination of resveratrol with doxorubicin or docetaxel in all tested cell lines while p-53 showed marginal elevation in MCF-7 and HepG2 cell lines. Additionally.